The big language model is infiltrating every aspect of the healthcare field at an unprecedented speed, from clinical assisted diagnosis to medical image analysis, from drug molecule discovery to personalized treatment plan formulation. AI technology is redefining the boundaries of modern medicine.
In terms of auxiliary diagnosis, medical AI systems based on big language models have demonstrated remarkable capabilities. Through training on massive medical literature, clinical guidelines, and case data, these models are able to understand patient symptom descriptions and provide possible differential diagnosis recommendations. In recent years, multiple studies have shown that GPT-4 level models have performed better than the average score line for human doctors in medical licensing exams. In visual recognition tasks such as skin lesion classification and retinal disease diagnosis, the accuracy of AI models is also comparable to that of specialist doctors.
Medical image analysis is one of the most mature application scenarios of AI in the medical field. Deep convolutional neural networks perform well in the interpretation of CT images, magnetic resonance imaging, and X-ray films. AI systems can detect and locate lung nodules within seconds, significantly reducing doctors' reading time. More importantly, AI can capture subtle signs of lesions that are difficult for the human eye to detect, playing a unique role in early cancer screening. At present, dozens of AI medical imaging products in China have obtained NMPA certification, covering multiple directions such as pulmonary nodules, fundus lesions, and fracture detection.
In the field of drug development, AI is changing the traditional "trial and error" model of new drug discovery. The traditional drug development cycle takes 10-15 years and costs an average of billions of dollars. AI can select the most promising lead compounds from millions of candidate molecules within weeks by generating chemical models and large-scale virtual screening. AlphaFold's breakthrough in protein structure prediction has further accelerated this process. Since 2025, multiple AI pharmaceutical companies have advanced multiple candidate drugs to the clinical trial stage, covering fields such as tumors, neurological diseases, and rare diseases.
However, the application of AI in the medical field also faces significant challenges. Data privacy and security are the primary issues - medical data involves the most sensitive personal information of patients, and how to effectively utilize data while protecting privacy is a persistent challenge. In addition, the "black box" nature of AI models is particularly sensitive in medical scenarios, where both doctors and patients need to understand why the model makes specific judgments. The regulatory framework is still evolving - the approval standards for AI medical devices in various countries have not yet been fully unified.
Looking ahead, with the maturity of technologies such as federated learning and interpretable AI, the application of AI in the medical field will gradually evolve from an auxiliary tool to an indispensable part of the medical decision-making chain. The "hybrid intelligence" model of collaborative work between humans and AI may become the mainstream paradigm of future medical practice.
This article is a comprehensive compilation of AI medical device approval information publicly released by the National Medical Products Administration (NMPA) and AI medical related research papers published in international academic journals.